Europe / Top 5 Pharma R&D Spenders
The Top Five countries in Europe ranked by amount spent on pharma R&D. While some of the continent’s largest…
Dr. Franz Köhler Chemie
Last updated: 13.02.2014
Address: Werner-von-Siemens-Straße 22-28
64625 Bensheim
Tel: +49 (0) 6251 – 1083-0
Web: http://www.koehler-chemie.de/deutsch/startseite/
Company description
Dr. Franz Köhler Chemie, the company, specialises in organ-protecting solutions, therapeutics, x-ray contrast agents and antidotes. On this basis, Dr. Gernot Köhler, from the second generation, has expanded the company into an innovative, research-intensive and high performance pharmaceuticals company in Alsbach, the USA and Russia. Distributing associates represent the company worldwide. Internal research makes innovative products and continuous development possible. As a result, new therapeutic approaches are formulated in close co-operation with qualified doctors and research is carried out effectively and dependent on requirements. “We are at your service” is the mission statement with which we shall continue to contribute to advances in science and medicine in the interests of the user and patients alike.
Dr. Franz Josef Köhler founded the company in 1959. He is the founder of aspartic therapy and a promoter of organ-protecting solutions. In his honour, the German Society for Thoracic and Cardiovascular Surgery has awarded the “Franz J. Köhler Award” every year since 1990, for outstanding work in the field of organ protection with special emphasis on the heart. His son, Dr. Gernot Köhler, has headed this modern medium sized company since 1984, guiding it into new areas of business.
Dr. Franz Köhler Chemie produces at two German locations thereby meeting the increasing international demand for organ-protecting solutions. The products, perfusion, infusion and injection solutions from Alsbach and Bensheim in South Hesse are in a leading position internationally.
Products and services
Related
Europe / Health Technology Assessment in the EU: Back and Forth in Giant Strides
Writing in the August edition of DIA’s Global Forum, Sanofi R&D’s Thomas Kühler outlines the bumpy…
Europe / New EFPIA President Hubertus von Baumbach on Building Back Better from COVID & a Healthier European Future
Boehringer Ingelheim’s Hubertus von Baumbach, the newly appointed president of the European Federation of…
Germany / Merck KGaA Expecting More COVID-Related Deals; Digital Health Woes; CureVac Vaccine Potential vs Variants
The latest news from German pharma, including a new US leadership team and more COVID-related investment at Merck…
Germany / Highest Honours for BioNTech Founders; Bayer’s Growth Predictions; Merck Making Further French Investments
A roundup of some of the most important recent news from German pharma, including state honours for the founders of…
Germany / STADA’s Bold Bets on M&A
After a year of growth and acquisitions, 125-year-old German generics manufacturer STADA is showing a willingness…
Germany / The Biotech Behind Pfizer’s COVID-19 Vaccine Candidate
German biotech BioNTech has been thrust into the global spotlight thanks to its collaboration with global giant…
Pharma Faces / Teresa Rodó, Head of Global Healthcare Operations, Merck
PharmaBoardroom recently sat down with Merck’s EVP and Head of Global Healthcare Operations, Teresa Rodó to…
Merck KGaA / Big-Ticket Investments in Manufacturing Scale & Digital Innovation
Merck KGaA has moved to continuously expand its manufacturing capacity and capability in recent years with a number…
Europe / A New Approach to Health Crises in France & Germany
Emmanuel Macron and Angela Merkel recently put their heads together to come up with a health strategy that would…
News Roundup / German Pharma: February 2020
Some of the top recent stories from Germany, Europe’s leading pharma market according to CPhI, including big…
Bayer: Betting Big on Cell & Gene Therapy
Bayer’s latest move to buy out BlueRock Therapeutics comes with a price tag of USD 600 million in total as…
